Microcap Ledger Monopar Therapeutics $MNPR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Wilmette, IL
- Fiscal year end
- December 31
- Shares outstanding
- 6,712,172 [10-Q 2026-08-12]
What the company doesAI summary of filing
Monopar Therapeutics is a clinical-stage biopharmaceutical company that develops drug candidates through licensing agreements. The company's primary product candidate is ALXN1840, licensed from AstraZeneca for the treatment of Wilson disease, which has received Orphan Drug Designation and Fast Track designation from the FDA. The company also has MNPR-101, a radiopharmaceutical candidate developed jointly with NorthStar. Monopar is pre-revenue and has not yet received governmental approval for any product, brought any product to market, or generated sales. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$9.21M | −$6.72M | $52.76M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $0.00 | −$13.72M | −$12.20M | $61.83M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $0.00 | −$15.59M | −$6.40M | $45.82M | [10-K 2025-03-31] |
- Quarterly cash burn
- −$3.36M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 5,277,796 | [10-Q 2024-11-08] |
| 2025-03-14 | 6,112,593 | [10-K 2025-03-31] |
| 2025-04-30 | 6,115,214 | [10-Q 2025-05-13] |
| 2025-07-31 | 6,169,961 | [10-Q 2025-08-12] |
| 2025-10-31 | 6,682,584 | [10-Q 2025-11-13] |
| 2026-03-17 | 6,692,140 | [10-K/A 2026-04-01] |
| 2026-04-30 | 6,699,062 | [10-Q 2026-05-14] |
| 2026-07-31 | 6,712,172 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-08-29; declared effective 2025-09-09 [S-3 2025-08-29]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Starr Christopher M | exercise | 8,400 | $0.01 | [4 2026-10-05] |
| 2026-10-01 | Starr Christopher M | sell | 4,631 | $78.09 | [4 2026-10-05] |
| 2026-10-01 | Starr Christopher M | sell | 2,970 | $78.82 | [4 2026-10-05] |
| 2026-10-01 | Starr Christopher M | sell | 799 | $79.67 | [4 2026-10-05] |
| 2026-09-30 | Cittadine Andrew | exercise | 4,384 | — | [4 2026-10-02] |
| 2026-09-30 | Cittadine Andrew | other | 1,944 | $79.67 | [4 2026-10-02] |
| 2026-09-30 | Robinson Chandler | exercise | 9,801 | — | [4 2026-10-02] |
| 2026-09-30 | Robinson Chandler | other | 4,344 | $79.67 | [4 2026-10-02] |
| 2026-09-30 | Vu Quan Anh | exercise | 614 | — | [4 2026-10-02] |
| 2026-09-30 | Vu Quan Anh | other | 180 | $79.67 | [4 2026-10-02] |
| 2026-09-24 | Robinson Chandler | exercise | 14,056 | $30.00 | [4 2026-09-28] |
| 2026-09-24 | Robinson Chandler | exercise | 15,000 | $14.00 | [4 2026-09-28] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-22 | 8-K | Regulation FD disclosure |
| 2026-06-30 | 8-K | Regulation FD disclosure |
| 2026-06-26 | 8-K | Regulation FD disclosure |
| 2026-06-23 | 8-K | Shareholder vote results |
| 2026-05-29 | 8-K | Regulation FD disclosure |
| 2026-05-19 | 8-K | Regulation FD disclosure |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 10-Q | Quarterly report |
Alerts for $MNPR
Email me when Monopar Therapeutics files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.